acc1601 |
CYLD |
phosphorylation |
Ser418 |
human |
Lymphoma |
HBL-1 |
acalabrutinib (ACP-196) |
Associated |
4.0 |
33827598
|
acc1602 |
CYLD |
phosphorylation |
Ser418 |
human |
Lymphoma |
OCI-Ly10 |
acalabrutinib (ACP-196) |
Associated |
4.0 |
33827598
|
acc1603 |
CYLD |
phosphorylation |
Ser418 |
human |
Lymphoma |
HBL-1 |
Rituximab |
Impairing |
5.0 |
33827598
|
acc1604 |
CYLD |
phosphorylation |
Ser418 |
human |
Lymphoma |
OCI-Ly10 |
Rituximab |
Impairing |
5.0 |
33827598
|
acc1605 |
DDR1 |
phosphorylation |
Tyr792 |
human |
Colorectal Cancer |
HCT116 |
Dapagliflozin |
Associated |
4.0 |
31979355
|
acc1606 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Bladder Cancer |
UM-UC-6 |
Dacomitinib |
Associated |
4.0 |
24166682
|
acc1607 |
ERK1 |
phosphorylation |
Thr202 |
human |
Bladder Cancer |
UM-UC-6 |
Dacomitinib |
Associated |
4.0 |
24166682
|
acc1608 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Bladder Cancer |
UM-UC-6 |
Dacomitinib |
Associated |
4.0 |
24166682
|
acc1609 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Bladder Cancer |
UM-UC-9 |
Dacomitinib |
Associated |
4.0 |
24166682
|
acc1610 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Bladder Cancer |
UM-UC-9 |
Dacomitinib |
Associated |
4.0 |
24166682
|
acc1611 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Mucoepidermoid Carcinoma |
UM-HMC-1 |
Tocilizumab |
Associated |
4.0 |
26287605
|
acc1612 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Mucoepidermoid Carcinoma |
UM-HMC-3A |
Tocilizumab |
Associated |
4.0 |
26287605
|
acc1613 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Mucoepidermoid Carcinoma |
UM-HMC-3B |
Tocilizumab |
Associated |
4.0 |
26287605
|
acc1614 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Colorectal Cancer |
HCT116 |
Auranofin + ICG-001 |
Associated |
4.0 |
34900688
|
acc1615 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Colorectal Cancer |
SW480 |
Auranofin + ICG-001 |
Associated |
4.0 |
34900688
|
acc1616 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Colorectal Cancer |
DLD-1 |
Auranofin + ICG-001 |
Associated |
4.0 |
34900688
|
acc1617 |
EGFR |
phosphorylation |
Tyr1173 |
human |
Lung Cancer |
HCC827 |
Erlotinib |
Associated |
4.0 |
27612423
|
acc1618 |
EGFR |
phosphorylation |
Tyr1173 |
human |
Lung Cancer |
NCI-H3255 |
Erlotinib |
Associated |
4.0 |
27612423
|
acc1619 |
EGFR |
phosphorylation |
Tyr1173 |
human |
Lung Cancer |
NCI-H1975 |
Erlotinib |
Associated |
4.0 |
27612423
|
acc1620 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Lung Cancer |
|
Erlotinib |
Enhancing |
5.0 |
26247735
|
acc1621 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Lung Cancer |
CL1-5 |
Curcumin |
Associated |
4.0 |
21858220
|
acc1622 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Lung Cancer |
A549 |
Curcumin |
Associated |
4.0 |
21858220
|
acc1623 |
EGFR |
ubiquitination |
unclear |
human |
Lung Cancer |
A549 |
Gefitinib |
Enhancing |
5.0 |
21858220
|
acc1624 |
EGFR |
ubiquitination |
unclear |
human |
Lung Cancer |
H1975 |
Gefitinib |
Enhancing |
5.0 |
21858220
|
acc1625 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Lung Cancer |
H1975 |
Curcumin |
Associated |
4.0 |
21858220
|
acc1626 |
EGFR |
ubiquitination |
unclear |
human |
Lung Cancer |
CL1-5 |
Curcumin |
Associated |
4.0 |
21858220
|
acc1627 |
EGFR |
ubiquitination |
unclear |
human |
Lung Cancer |
A549 |
Curcumin |
Associated |
4.0 |
21858220
|
acc1628 |
EGFR |
ubiquitination |
unclear |
human |
Lung Cancer |
H1975 |
Curcumin |
Associated |
4.0 |
21858220
|
acc1629 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Lung Cancer |
CL1-5 |
Gefitinib |
Impairing |
5.0 |
21858220
|
acc1630 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Lung Cancer |
A549 |
Gefitinib |
Impairing |
5.0 |
21858220
|
acc1631 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Lung Cancer |
H1975 |
Gefitinib |
Impairing |
5.0 |
21858220
|
acc1632 |
EGFR |
ubiquitination |
Tyr1068 |
human |
Lung Cancer |
CL1-5 |
Gefitinib |
Enhancing |
5.0 |
21858220
|
acc1633 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Lung Cancer |
PC9 |
Docetaxel + Gefitinib |
Associated |
4.0 |
24682085
|
acc1634 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Head and Neck Cancer |
|
Lysophosphatidic acid (LPA) |
Associated |
4.0 |
12414665
|
acc1635 |
ERK1 |
phosphorylation |
Thr202 |
human |
Ovarian Cancer |
SK-OV-3 |
DpdtC |
Associated |
4.0 |
29467385
|
acc1636 |
ERK1 |
phosphorylation |
Thr202 |
human |
Ovarian Cancer |
SK-BR-3 |
DpdtC |
Associated |
4.0 |
29467385
|
acc1637 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Ovarian Cancer |
SK-OV-3 |
DpdtC |
Associated |
4.0 |
29467385
|
acc1638 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Ovarian Cancer |
SK-BR-3 |
DpdtC |
Associated |
4.0 |
29467385
|
acc1639 |
ERK2 |
phosphorylation |
Thr185 |
human |
Ovarian Cancer |
SK-OV-3 |
DpdtC |
Associated |
4.0 |
29467385
|
acc1640 |
ERK2 |
phosphorylation |
Thr185 |
human |
Ovarian Cancer |
SK-BR-3 |
DpdtC |
Associated |
4.0 |
29467385
|
acc1641 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Ovarian Cancer |
SK-OV-3 |
DpdtC |
Associated |
4.0 |
29467385
|
acc1642 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Ovarian Cancer |
SK-BR-3 |
DpdtC |
Associated |
4.0 |
29467385
|
acc1643 |
ERK1 |
phosphorylation |
Thr202 |
human |
Lung Cancer |
H1666 |
Gefitinib |
Impairing |
5.0 |
22777356
|
acc1644 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Lung Cancer |
H1666 |
Gefitinib |
Impairing |
5.0 |
22777356
|
acc1645 |
ERK2 |
phosphorylation |
Thr185 |
human |
Lung Cancer |
H1666 |
Gefitinib |
Impairing |
5.0 |
22777356
|
acc1646 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Lung Cancer |
H1666 |
Gefitinib |
Impairing |
5.0 |
22777356
|
acc1647 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Lung Cancer |
PC9GR |
Gefitinib |
Impairing |
5.0 |
31671073
|
acc1648 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Lung Cancer |
PC9GR |
Osimertinib |
Impairing |
5.0 |
31671073
|
acc1649 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Pancreas Cancer |
L3.6pl |
Gefitinib |
Associated |
4.0 |
16585207
|
acc1650 |
AKT |
phosphorylation |
Ser473 |
human |
Pancreas Cancer |
L3.6pl |
Gefitinib |
Associated |
4.0 |
16585207
|